Clinical studies have suggested that a recombinant FGF21 analog (pegozafermin) can be used to treat nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia [34,35]. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.